Impact of TheraWorx Foam on Symptom Relief in Thumb Arthritis

Phase 3

Completed

Brief Summary: Thumb carpometacarpal osteoarthritis (CMC OA) affects up to 33% of people over the age of 40, which leads to inflammation, pain, and weakness of the CMC joint. Treatment modalities are both conservative and surgical with surgical options including osteotomy, bone excision, ligament reconstruction, and various prosthetic implants. The conservative treatment options, however, are limited to NSAIDs and bracing or steroid injections.

Advances in topical therapies have the potential to deliver focused treatment to the CMC joint. Novel treatment of inflammation can potentially reduce inflammation and pain associated with progressing osteoarthritis. Theraworx Relief is an FDA registered foam that has theoretical impact on inflammation reduction in human subjects treated with the topical foam.

Detailed Description: This pilot study seeks to investigate potential benefit in the use of Theraworx Foam in patients diagnosed with thumb CMC OA. Patients presenting to the upper extremity orthopedic surgery clinic for thumb/hand/wrist pain will be diagnosed by a Board Certified Hand Surgeon as per standard protocols. Patients who are recommended to follow a conservative treatment modality and are interested in participating in this study will be randomized into treatment or control groups. Both groups will undergo symptom assessment, strength testing, and range of motion testing prior to starting the standard conservative treatment of bracing. The treatment group will use the TheraWorx topical foam and the compression wrap nightly for 2 weeks for at least 6 hours per night. Control group will use a compression wrap for the same time period. Both groups will return at 1 and 2 weeks for repeat strength and range of motion testing and symptom assessment.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Recent corticosteroid injection into the thumb joint
Non-English speaking
skin lesions or rashes on the thumb
current use of topical anti-inflammatory medications
concomitant thumb/wrist diagnoses that would impact the results (as determined by the PI)
known allergy to magnesium

Arm && Interventions

Group	Intervention	Description
Foam and Compression Wrap	Theraworx	Patients will use Theraworx foam and a compression wrap
Placebo Foam and Compression Wrap	Placebo	Patients will use placebo foam and a compression wrap
Foam alone	Theraworx	Patients will use Theraworx foam without compression wrap

Primary Outcome Measures

Name	Time	Method
Pinch Strength	2 weeks	This measures pinch strength in pounds (0 is no pinch strength and 40 is maximum pinch strength), mean pinch in pounds reported at 2 weeks
Disabilities of the Arm, Shoulder, and Hand (DASH) Score	2 weeks	patient rated outcome score on scale of 0-100, with 0 being no disability and 100 complete disability, mean value at 2 weeks is reported
Thumb Range of Motion	2 weeks	This measures range of motion of the thumb in degrees from 0-90 degrees (0 degrees would be no motion and 90 degrees full motion), 2 week data is presented as a mean.
Grip Strength	2 weeks	This measures grip strength in pounds (0 is no grip strength 150 is maximum grip strength), mean grip strength in pounds reported at 2 weeks
Numeric Pain Rating Scale	2 weeks	patient rated pain on scale of 0-10 (0 no pain and 10 maximum pain). The mean score at 2 weeks is reported, not the change from baseline.

Secondary Outcome Measures

Name	Time	Method

Locations (3): Kaufmann Building
🇺🇸
Pittsburgh, Pennsylvania, United States
Montefiore Hospital
🇺🇸
Pittsburgh, Pennsylvania, United States
University of Pittsburgh Medical Center
🇺🇸
Pittsburgh, Pennsylvania, United States